Merck continues to ride cancer drug Keytruda higher
Shares of Merck (MRK) closed up 3.50% today, October 29, after the company reported better than expected third quarter earnings. On a Non-GAAP basis earrings of $1.51 a share beat the Wall Street consensus by 27 cents a share. Revenue of $12.4 billion fell 6.7% year...
Government action on drug prices seems far, far away
The format was familiar: Seven CEOs sit in front of a Senate Committee probing their industry’s business practices. But whereas a Congressional hearing a decade ago marked a key moment in what was a costly public reckoning for the tobacco industry, today’s...
Merck moves lower in spite of earnings beat
This morning before the New York markets opened Merck (MRK) reported earnings of $1.05 a share, ahead of the $1.00 a share forecast by Wall Street analysts. Earnings were up 19.3% from the first quarter of 2017. Revenue grew 6% to $10 billion. That narrowly missed the...
Adding Merck to my Dividend Portfolio
News out of the imuno-oncology sector of the biotech world has hit stocks in my portfolios such as Incyte (INCY) and Nektar Therapeutics (NKTR) hard. But, I’d argue that it has left Keytruda and its owner Merck (MRK) in a measurably stronger position in the...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!